Validation of MSIntuit as an AI-based pre-screening tool for MSI detection from colorectal cancer histology slides

Author:

Saillard CharlieORCID,Dubois Rémy,Tchita OussamaORCID,Loiseau Nicolas,Garcia Thierry,Adriansen Aurélie,Carpentier Séverine,Reyre Joelle,Enea DianaORCID,von Loga Katharina,Kamoun Aurélie,Rossat Stéphane,Wiscart Corentin,Sefta Meriem,Auffret Michaël,Guillou LionelORCID,Fouillet Arnaud,Kather Jakob NikolasORCID,Svrcek Magali

Abstract

AbstractMismatch Repair Deficiency (dMMR)/Microsatellite Instability (MSI) is a key biomarker in colorectal cancer (CRC). Universal screening of CRC patients for MSI status is now recommended, but contributes to increased workload for pathologists and delayed therapeutic decisions. Deep learning has the potential to ease dMMR/MSI testing and accelerate oncologist decision making in clinical practice, yet no comprehensive validation of a clinically approved tool has been conducted. We developed MSIntuit, a clinically approved artificial intelligence (AI) based pre-screening tool for MSI detection from haematoxylin-eosin (H&E) stained slides. After training on samples from The Cancer Genome Atlas (TCGA), a blind validation is performed on an independent dataset of 600 consecutive CRC patients. Inter-scanner reliability is studied by digitising each slide using two different scanners. MSIntuit yields a sensitivity of 0.96–0.98, a specificity of 0.47-0.46, and an excellent inter-scanner agreement (Cohen’s κ: 0.82). By reaching high sensitivity comparable to gold standard methods while ruling out almost half of the non-MSI population, we show that MSIntuit can effectively serve as a pre-screening tool to alleviate MSI testing burden in clinical practice.

Publisher

Springer Science and Business Media LLC

Subject

General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry,Multidisciplinary

Reference32 articles.

1. https://www.fda.gov/news-events/press-announcements/fda-approves-first-cancer-treatment-any-solid-tumor-specific-genetic-feature.

2. Molecular testing strategies for Lynch syndrome in people with colorectal cancer: recommendations. NICE Pathways. https://www.nice.org.uk/guidance/dg27/chapter/1-Recommendations (Accessed 13 Nov 2019).

3. National Comprehensive Cancer Network Genetic/Familial High-Risk Assessment: Colorectal (Version 1 2018); Available online: https://www.nccn.org/professionals/physician_gls/pdf/genetics_colon.pdf.

4. Henry, J. T. & Johnson, B. Current and evolving biomarkers for precision oncology in the management of metastatic colorectal cancer. Chin. Clin. Oncol. 8, 49 (2019).

5. Bychkov, A. & Fukuoka, J. Evaluation of the global supply of pathologists. Lab. Invest. 102, 1361–1361 (2022).

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3